cells

Multiple Cancer Types Trials

Multiple Cancer Types
(AB308 + zimberelimab; ARC-12 study)

Overview

A Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab in participants with advanced malignancies.

Key Eligibility Criteria

  • Participants must have performance score of 0 or 1 with measurable disease as per radiographic evaluation
  • Disease specific criteria for dose escalation includes participants with any type of solid tumor for which no treatment is currently available, or participants with non-Hodgkin Lymphoma that has progressed on prior chemotherapy and are unable to receive stem cell transplant or adoptive cell transfer. Participants may have received up to 5 prior anti-cancer therapies and an unlimited number of prior hormonal therapies.
  • No prior treatments with an anti-TIGIT antibody, active or prior autoimmune disease that required treatment in past 3 years or prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic agents, or use of other investigational drugs within 28 days before first dose of study treatment.

AB308 + zimberelimab Clinical Trial Locations

clinicaltrials.gov

arrow